iiinova — where your digital self keeps evolving

Andrew Lloyd ALA @andrewlloydala.bsky.social · 06/10/2026

[ALA Client News] Archeon Medical secures $9M (€7.5M) Series A to advance clinical validation of ventilation system for cardiac arrest patients ala.associates/funding/arch... #funding #medtech #cardiacarrest

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/09/2026

[ALA Client News] Provepharm enters fluorescence imaging market with US and UK launch of Zyogreen, its ready-to-use indocyanine green dye ala.associates/product-laun... #fluorescenceimaging #medicaldyes

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/09/2026

[ALA Client News] iPerf concludes promising clinical trial of novel dual-lumen femoral arterial cannula for cardiopulmonary support ala.associates/clinical/ipe... #clinicaltrial #ECMO #CEC

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/09/2026

[ALA Client News] Novadip secures €10.4 million financing to complete pivotal Phase 3 trial ala.associates/funding/nova... #funding #biotech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 15/09/2026

[ALA Client News] Axoltis Pharma announces topline Phase 2 results for NX210c in Amyotrophic Lateral Sclerosis ala.associates/clinical/axo... #ALS #neurology #clinicaltrial

011

Andrew Lloyd ALA @andrewlloydala.bsky.social · 11/09/2026

🎙️ Media Training at Future4Care This week, our ALA team members Celine Gonzalez and Lorraine Walters shared practical advice with startups on interview preparation, key messages and building strong relationships with journalists, investors and KOLs. Thanks to everyone who joined! 🎥

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/09/2026

[ALA Client News] Ciliatech receives FDA IDE approval to initiate US feasibility study of INTERCIL® Uveal Spacer for glaucoma ala.associates/clinical/cil... #glaucoma #ophthalmology #medtech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/09/2026

[ALA Client News] Clean Cells launches Next-Generation Sequencing (NGS) offering for viral safety testing ala.associates/product-laun... #biopharma #bioinformatics

001

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/09/2026

[ALA Client News] SOFIPACA et Région Sud Investissement renouvellent leur confiance à Provepharm pour accompagner une nouvelle étape de son développement ala.associates/funding/sofi... #PACA #pharma #chirurgie

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 01/09/2026

[ALA Client News] Amyl Therapeutics secures €8.25M Series A extension to validate novel neurodegenerative disease platform ala.associates/funding/amyl... #funding #biotech #neurology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 30/07/2026

[ALA Client News] Clean Cells acquires Anaquant to expand analytical capabilities in biomanufacturing quality control ala.associates/corporate/cl... #biomanufacturing #qualitycontrol

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/07/2026

Coverage included @biocentury.bsky.social, @endpts.com, The Pharma Letter, Labiotech, BioWorld, EU-Startups and Citeline. Full case study 👇 ala.associates/case-studies...

ala.associates

Exciva | Andrew Lloyd & Associates

030

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/07/2026

[Client Case Study] In 2026, ALA collaborated with @exciva-gmbh.bsky.social on three news releases covering a Series B fundraising, an executive appointment and a clinical trial launch The campaign generated 150+ media coverages, reaching an audience of 63M+ readers.

110

Andrew Lloyd ALA @andrewlloydala.bsky.social · 13/07/2026

[ALA Client News] Caixa Capital Risc rebrands as Criteria Capital Risc and targets €300M investment volume by 2030 ala.associates/corporate/ca... #funding #biotech #tech

020

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

7️⃣ Dr Yoon Young Lee PhD, at Meteor Biotech, authored an article for Clinical Laboratory International outlining the emerging potential of spatially resolved cell sorting for advanced tumor analysis. Links to all articles can be found in our Linktree 👉 linktr.ee/ala_associates #biotech #medtech #PR

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

6️⃣ @Philippe Bencteux, CEO of Robocath, joined Thomas Hickey on Med Tech Gurus to discuss how robotic platforms are redefining precision, safety, and access in cardiovascular procedures.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

5️⃣ Vygon US in Vascular News. The US subsidiary received approval from Health Canada to commercialize Stiletto, its new generation of extended dwell catheters integrating SlipStream technology. @vygongroup.bsky.social

110

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

4️⃣ Lucy Thulot, Head of Production and Alexis Rossignol, R&D project manager at Clean Cells co-authored an article in European Biopharmaceutical Review exploring the cell bank strategy in biologics manufacturing.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

3️⃣ Meteor Biotech in Discover Pharma. The spatial omics specialist recently joined the Brain Organoids Consortium, a South Korean Government initiative to advance the world’s first integrated commercialization platform for advanced brain organoids.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

2️⃣ Clean Cells in @lesechosfr.bsky.social . Earlier this month, Clean Cells acquired Stem Genomics, including its stability testing platform, to boost its cell therapy quality control suite.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

Celebrating our clients' media successes 🌟 We’re proud to share some of our clients’ highlights in the media published in June: 1️⃣ Grapheal in Aquatech. Vincent Bouchiat shared his expert insights on European regulations on PFAS and advancements in portable detection technologies.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 29/06/2026

[ALA Client News] Genoskin Doubles US Foothold to Launch Local Primary Human Mast Cell Production for North American Customers ala.associates/corporate/ge... #mastcells #drugdiscovery

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 26/06/2026

🎙️[ALA Client in the News] Tune into the latest episode of Med Tech Gurus, where Philippe Bencteux, CEO of Robocath joins Thomas Hickey to discuss how robotic platforms are redefining precision, safety, and access in cardiovascular procedures. www.youtube.com/watch?v=L3KA... #cardiovascular #robotics

youtube.com

Robotics in the Cath Lab | Philippe Bencteux, MD | The Future of Robotic Angioplasty

YouTube video by Med Tech Gurus

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/06/2026

[ALA Client News] Kayentis launches interactive eConsent solution to simplify and improve patient understanding of clinical trials ala.associates/product-laun... #clinicaltrials #digitalhealth #eCOA

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 23/06/2026

[ALA Client News] Meteor Biotech joins consortium on seven-year brain organoids commercialization project ala.associates/partnership/... #neurology #drugdiscovery

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 22/06/2026

We attended @vivatech.bsky.social 2026 in Paris last week! An incredible opportunity to connect with some of the most innovative companies shaping the future of technology and healthcare. We look forward to sharing new inspiring stories and news in the coming weeks #VivaTech2026 #deeptech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 18/06/2026

[ALA Client News] Clean Cells acquires Stem Genomics to strengthen cell therapy quality control and expand US presence ala.associates/corporate/cl... #biopharma #stemcells

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/06/2026

[ALA Client News] Vygon Corporation receives Health Canada approval to commercialize Stiletto™ extended dwell catheters ala.associates/product-laun... #medtech #hospital @vygongroup.bsky.social

022

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/06/2026

[ALA Client News] Meteor Biotech delivers talk at Spatial Omics 2026 on gaps in spatial biology mapping ala.associates/events/meteo... #SpatialOmics @vibtrainconf.bsky.social

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 12/06/2026

🫵 We want to hear from you! Is there a technical term you struggle to explain to non-experts? Contact us to learn more about how ALA can prepare you to handle your next interview. Book your free 30-minute consultation now👇 lunacal.ai/andrewlloyda...

lunacal.ai

Meeting | Book appointment with Juliette Schmitt on lunacal.ai

Schedule an appointment with Juliette Schmitt

020

Andrew Lloyd ALA @andrewlloydala.bsky.social · 12/06/2026

💡TIP #4: Tailor your language to the media you are speaking to It’s important to adapt how you explain your technology to different audiences. Specialized and trade media require a different approach. They may speak your technical language, but they might not be fluent. #PR #mediatraining

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/06/2026

[ALA Client News] Grapheal secures €2.5M from EIC Accelerator program to develop fast, field-deployable graphene sensors for ultra-trace, real-time PFAS detection ala.associates/funding/18767/ @ec.europa.eu #PFAS #EIC #deeptech

020

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

6️⃣ Cathpax in @auntminnieeurope.bsky.social. The radiation protection company recently announced the commercial launch of Nova-X in the EMEA. #biotech #medtech #CDMO #PR Read the full news releases on our website 👉 ala.associates/newsroom/

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

5️⃣ @exciva-gmbh.bsky.social in European Pharmaceutical Manufacturer. The company has appointed distinguished biotech executive Mark Altmeyer as chairman of its board of directors.

110

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

4️⃣ Mark Meichenin, co-founder and scientific director of Clean Cells shared his perspective on the complexity of modalities reshaping CDMO differentiation and specialization strategies with Pharma's Almanac.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

3️⃣ Robocath in Cardiac Interventions Today. The medtech company has completed enrollment for a first-in-human trial of its next-generation robotic platform for PCI.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

2️⃣ BleednFire launch and funding were covered in the The Pharma Letter. The startup focusing on first-in-class RNA therapies for rare bleeding disorders was also listed by the publication as 'one to watch.'

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

Celebrating our clients' media successes 🌟 Here are some of our May highlights: 1️⃣ Estelle Haenel, CMO of Kayentis authored an article for International Clinical Trials on the value of wearables in eCOAs.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 29/05/2026

💡TIP #3: if all spokespersons are media-trained, the delivery of your company messages will be consistent and stronger -> Interested in media training? See how ALA’s media training has helped our clients feel more confident and prepared for every interview

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/05/2026

[ALA Client News] Cathpax roll-outs new radiation protection system Nova-X® across EMEA following very promising clinical results ala.associates/clinical/cat... #medtech #neuroradiology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 27/05/2026

[ALA Client News] BLEEDnFIRE Therapeutics launches with non-dilutive funding to advance first-in-class pan-indication therapy for rare bleeding disorders ala.associates/funding/blee... #hemophilia #innovation #hematology @inselgruppe.bsky.social @unibe.ch

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

6️⃣ Clean Cells in Brief Glance. The article highlights the CDMO's ambitions in the South Korean market and its recent visit, where the team participated in #BIOKOREA alongside sister company Naobios. #biotech #CDMO #PR Read the full news releases on our website ala.associates/newsroom/

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

5️⃣ Kahimmune Therapeutics in GenomeWeb. The immuno-oncology focused biotech has partnered with @gustaveroussy.fr to support the selection of the company's first #oncology therapeutic candidate.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

4️⃣ Kayentis in Pharmafile. The clinical trials specialist has joined forces with RWS to strengthen clinical outcomes data in Central Nervous System (CNS) and other complex clinical trials. #clinicaltrials

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

3️⃣ Jean-Pascal Zambaux spoke with Marion Baschet Vernet at Pharmaceutiques about PLL Therapeutics dual-approach, combining a novel therapeutic and diagnostic tool, for the treatment and management of #ALS.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

2️⃣ Romain Membrat and Olivier De Beaumont from Provepharm authored an article on the future of NIR-II FGS in precision surgery for Innovations in Pharmaceutical Technology. #precisionsurgery

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

Celebrating our clients' media successes 🌟 Here are some of our April highlights: 1️⃣ Exciva in Drug Discovery World. The biotech company has dosed the first patient in a clinical trial evaluating the safety and efficacy of Deraphan for the treatment of agitation in patients with #Alzheimers disease.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 12/05/2026

[ALA Client News] Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board ala.associates/appointment/... #alzheimers #neuropsychiatric #biopharma

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 11/05/2026

[ALA Client News] Robocath completes enrollment in First-In-Human (FIH) study of next-gen robotic platform in interventional cardiology ala.associates/clinical/rob... #robotics #cardiology #clinicaltrials

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/04/2026

[ALA Client News] Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round ala.associates/clinical/exc... #alzheimers #clinicaltrial #seriesB

100